A dramatic increase in serum CK levels after switching from oral to intravenous administration of LEV

Journal Article · 10 October 2019 · Neurology and Clinical Neuroscience

DOI: https://doi.org/10.1111/ncn3.12336 · OSTI ID:1570047

Takemoto, Mami  ^[1]; Yunoki, Taijun ^[1]; Sato, Kota  ^[1]; Hishikawa, Nozomi ^[1]; Yamashita, Toru  ^[1]; Ohta, Yasuyuki ^[1]; Shang, Jingwei ^[1]; Abe, Koji ^[1]

---

1. Department of Neurology Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan

Abstract The authors report on a 22‐year‐old Japanese woman who started oral administration of 1000 mg levetiracetam (LEV) for her epilepsy after the second convulsive seizure. She was free from seizures for the subsequent 111 days, but a third tonic‐clonic seizure happened and she was transferred to our hospital (Day 1). Her consciousness state was drowsy and 1000 mg LEV continued for two days, but intravenously. Although her state became clear, her serum creatine kinase (CK), myoglobin (Mb), and creatine (Cre) levels were significantly elevated (18 179 IU/L, 2783 ng/mL, and 0.8 mg/mL) with a peak at Day 5 of CK 26, 189 IU/L. After stopping intravenous injection of LEV, serum CK returned to its normal level promptly. The present case suggests that we should take more care in monitoring for rhabdomyolysis on switching from oral to intravenous administration of LEV.

• Sponsoring Organization: USDOE
• OSTI ID: 1570047
• Journal Information: Neurology and Clinical Neuroscience, Journal Name: Neurology and Clinical Neuroscience Journal Issue: 1 Vol. 8; ISSN 2049-4173
• Publisher: Wiley-BlackwellCopyright Statement
• Country of Publication: Country unknown/Code not available
• Language: English